Immix Biopharma, Inc.
NASDAQ:IMMX
2.09 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | -89.517 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.005 | 0.002 | 0.002 | 0.002 | 0.001 |
| Gross Profit
| 0 | -0.005 | -89.519 | -0.002 | -0.002 | -0.001 |
| Gross Profit Ratio
| 0 | 0 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.293 | 8.735 | 4.196 | 0.127 | 0.248 | 0.583 |
| General & Administrative Expenses
| 11.382 | 7.406 | 4.023 | 1.225 | 0.206 | 0.259 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.382 | 7.406 | 4.023 | 1.225 | 0.206 | 0.259 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0.001 | 0 |
| Operating Expenses
| 22.675 | 16.141 | 8.219 | 1.352 | 0.454 | 0.842 |
| Operating Income
| -22.675 | -16.141 | -8.219 | -1.352 | -0.454 | -0.842 |
| Operating Income Ratio
| 0 | 0 | 0.092 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.017 | 0.572 | -0 | -23.026 | -0.676 | -0.11 |
| Income Before Tax
| -21.657 | -15.569 | -8.219 | -24.378 | -1.13 | -0.952 |
| Income Before Tax Ratio
| 0 | 0 | 0.092 | 0 | 0 | 0 |
| Income Tax Expense
| 0.041 | 0.026 | 0.01 | 0.006 | 0.018 | 0.021 |
| Net Income
| -21.613 | -15.426 | -8.23 | -24.384 | -1.148 | -0.973 |
| Net Income Ratio
| 0 | 0 | 0.092 | 0 | 0 | 0 |
| EPS
| -0.76 | -0.89 | -0.62 | -1.84 | -0.15 | -0.29 |
| EPS Diluted
| -0.76 | -0.89 | -0.62 | -1.84 | -0.15 | -0.29 |
| EBITDA
| -21.542 | -16.136 | -8.217 | -1.35 | -0.452 | -0.841 |
| EBITDA Ratio
| 0 | 0 | 0.092 | 0 | 0 | 0 |